Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.

Hironaga SatakeTamotsu SagawaKoshi FujikawaYukimasa HatachiHisateru YasuiMasahito KotakaTakeshi KatoAkihito Tsuji

Published in: Cancer chemotherapy and pharmacology (2018)

Salvage chemotherapy with irinotecan plus ramucirumab was well-tolerated by patients previously treated for AGC. RD was defined as irinotecan 150 mg/m2 in combination with ramucirumab 8 mg/kg.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
neoadjuvant chemotherapy
squamous cell carcinoma
lymph node